Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-04

Study Completion Date

2017-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and tolerability of ceftaroline for the treatment of Late Onset Sepsis in neonates and young infants aged 7 to \<60 days

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pentoxifylline and Late Onset Sepsis in Preterm Infants

NCT02163174

Neonatal Late Onset Sepsis

COMPLETED PHASE3

Pentoxifylline Dose Optimization in Neonatal Sepsis

NCT04152980

Neonatal Late Onset Sepsis

COMPLETED PHASE3

Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.

NCT05981079

Late-Onset Neonatal Sepsis

UNKNOWN PHASE4

Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis

NCT02503761

Late Onset Neonatal Sepsis

COMPLETED PHASE3

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

NCT05347238

Late-Onset Neonatal Sepsis Extreme Prematurity Neonatal Hypotension

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicentre, multinational, open-label, single treatment arm study of intravenous (IV) ceftaroline fosamil and ampicillin, plus an optional aminoglycoside of choice, in hospitalized neonates and young infants aged 7 to \< 60 days with late-onset sepsis (LOS).

Baseline assessments for study eligibility will occur within 36 hours before administration of the first dose of study therapy. Study Day 1 is defined as the 24-hour period starting at the onset of the first administration of study therapy. Thereafter, subsequent Study Days are to follow the same pattern.

Safety assessments will occur throughout the study. Clinical outcome evaluations will occur at End-of-Therapy (EOT; within 24 hours after completion of last infusion) and Test-of-Cure (TOC; 8 to 15 days after the last dose of study therapy).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Late-onset Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ceftaroline Fosamil

Group Type EXPERIMENTAL

Ceftaroline Fosamil

Intervention Type DRUG

Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).

Ampicillin

Intervention Type DRUG

Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.

Aminoglycoside

Intervention Type DRUG

Optional, will be given as per local standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ceftaroline Fosamil

Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).

Intervention Type DRUG

Ampicillin

Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.

Intervention Type DRUG

Aminoglycoside

Optional, will be given as per local standard of care.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zinforo, Teflaro

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent in writing from parent(s) or other legally-acceptable representative(s);
* Male or female, gestational age ≥34 weeks, and chronological age 7 to \<60 days at the time of screening;
* Diagnosis of sepsis within 36 hours before enrolment, defined as the presence of at least 2 clinical criteria and at least 1 laboratory criterion in the presence of or as a result of suspected or proven bacterial infection that requires IV antibiotic therapy;
* Patients must meet at least 2 of the following clinical criteria :Hypothermia (\<36°C) OR fever (\>38.5°C); Bradycardia OR tachycardia OR rhythm instability; Urine output 0.5 to 1 mL/kg/h OR hypotension OR mottled skin OR impaired peripheral perfusion; Petechial rash OR sclerema neonatorum; New onset or worsening of apnoea episodes OR tachypnoea episodes OR increased oxygen requirements OR requirement for ventilation support; Feeding intolerance OR poor sucking OR abdominal distension; Irritability; Lethargy; Hypotonia:
* Patients must meet at least 1 of the following laboratory criteria: White blood cell count ≤4,000 × 109/L OR ≥20,000 × 109/L; Immature to total neutrophil ratio \>0.2; Platelet count ≤100,000 × 109/L; C-reactive protein (CRP) \>15 mg/L OR procalcitonin ≥2 ng/mL; Hyperglycaemia OR Hypoglycaemia; Metabolic acidosis.

Exclusion Criteria

* Documented history of any hypersensitivity or allergic reaction to any β-lactam antibiotic or aminoglycoside;
* At study entry, has confirmed infection with a pathogen known to be resistant to the combination of ceftaroline fosamil, ampicillin, and the optional aminoglycoside of choice OR confirmed viral, fungal, or parasitic pathogen as the sole cause of infection;
* Refractory septic shock within 24 hours before enrolment that does not resolve after 60 minutes of vasopressor therapy;
* Moderate or severe renal impairment defined as serum creatinine ≥2 times the upper limit of normal (× ULN) for age OR urine output \<0.5 mL/kg/h (measured over at least 8 hours) OR requirement for dialysis;
* Evidence of progressively fatal underlying disease, or life expectancy of ≤60 days;
* Documented history of seizure;
* Requiring or currently taking antiretroviral therapy for human immunodeficiency virus (HIV) or a child from an HIV positive mother;
* Proven or suspected central nervous system (CNS) infection (eg, meningitis, brain abscess, subdural abscess), osteomyelitis, endocarditis, or necrotizing enterocolitis (NEC);
* Any condition (eg, cystic fibrosis, urea cycle disorders), antepartum/peripartum factors, or procedures that would, in the opinion of the investigator, make the patient unsuitable for the study, place a patient at risk, or compromise the quality of data;
* Patient's parent(s) or legally-acceptable representative(s) involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Concurrent participation in another clinical study with an investigational product (IP), previous enrolment/participation in this study, or participation in another study of ceftaroline fosamil within 14 days before the intended start of the first dose of study therapy.

Minimum Eligible Age

7 Days

Maximum Eligible Age

59 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No